Biosimilars Don't Deserve Unique Name, Group Tells FDA
A major generic pharmaceutical industry group told the U.S. Food and Drug Administration on Thursday not to give unique names to generic versions of biologic drugs, saying identical names for branded...To view the full article, register now.
Already a subscriber? Click here to view full article